AML Video Channel
Explore the latest insights and summaries from experts in AML.
Therapeutic Agents
Rush University Medical Center
Is Post-HSCT Maintenance the SOC for AML?
FEATURING
Mark Levis
- 302 views
- May 29, 2024
- 4
Rush University Medical Center
What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies
FEATURING
Ehab Atallah
- 233 views
- May 29, 2024
- 1
Icahn School of Medicine at Mount Sinai
Integrating Targeted Therapies in AML
FEATURING
Hagop Kantarjian
- 423 views
- May 31, 2024
- 3
Stemline
A proven CD123 targeted therapy for BPDCN
FEATURING
Harry Erba
- 4,123 views
- September 4, 2024
- 9
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R AML
FEATURING
Wei-Ying Jen
- 248 views
- June 26, 2024
- 2
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors
FEATURING
Joshua Zeidner
- 69 views
- June 26, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Final 5-Year Results of Olutasidenib for Mutated IDH1 AML
FEATURING
Jorge Cortés
- 25 views
- June 28, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-GO vs. FLAG-IDA in Untreated Core Binding Factor AML
FEATURING
Gautam Borthakur
- 150 views
- July 1, 2024
- 2
Yale Cancer Center
The Role of Hypomethylating Agent Maintenance in AML
FEATURING
Rory Shallis
- 117 views
- July 1, 2024
Icahn School of Medicine at Mount Sinai
Therapeutic Targeting of RNA Splicing Factor Mutant Leukemias
FEATURING
Omar Abdel-Wahab
- 57 views
- July 2, 2024
SOHO Brazil 2024
The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML
FEATURING
Jeffrey Lancet
- 136 views
- July 11, 2024
SOHO Brazil 2024
Where I Use Azacitidine and Venetoclax in AML: Present and Future
FEATURING
Jeffrey Lancet
- 474 views
- July 11, 2024
- 4
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagraxofusp
FEATURING
Emanuele Angelucci
- 225 views
- July 23, 2024
- 1
Robert Zeiser
CSF1R's Role in Modulating Inflammation and Fibrosis in cGVHD
- 56 views
- August 13, 2024
- 1
University of Miami Sylvester Comprehensive Cancer Center
Current and Emerging Treatment Approaches for Patients With AML or MDS
FEATURING
Sangeetha Venugopal
- 136 views
- August 26, 2024
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Best of ASCO® 2024: CML, AML, ALL
FEATURING
Mariam Nawas
- 43 views
- September 3, 2024
Daniel Wolff
The Role of Axatilimab in Targeting CSF1R for Inflammation and Fibrosis in cGVHD – Recently FDA Approved
- 137 views
- September 6, 2024
- 1
Houston Methodist
Current Treatment Landscape in Myeloid Malignancies
FEATURING
Shilpan Shah
- 60 views
- September 11, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: IDH Mutated AML - Diagnostic and Treatment Paradigm
FEATURING
Teresa Macarulla Mercade
- 55 views
- September 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Targeted Therapies in AML With a Focus on FLT3 Inhibitors
FEATURING
Naval Daver
- 36 views
- October 8, 2024
Brittany Ragon
Targeting cGVHD: Mechanism of Action of Axatilimab Compared to Other Available Agents
- 24 views
- October 14, 2024
Najla El-Jurdi
CSF1R's Role in Modulating Inflammation & Fibrosis in cGVHD
- 34 views
- October 16, 2024
Yale Cancer Center
Myeloid Malignancies: Hot Topics in 2024
FEATURING
Nikolai Podoltsev
- 274 views
- October 21, 2024
Marina Konopleva
Considering Venetoclax in AML and ALL - Which Patients and Why
- 58 views
- October 23, 2024
- 2
Noah Merin
Axatilimab in cGVHD: Mechanism of Action and Comparison With Current Therapeutic Agents
- 88 views
- November 10, 2024
University of Colorado Division of Hematology
2024 Updates in AML
FEATURING
Christine McMahon
- 762 views
- April 16, 2024
- 6
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 912 views
- April 16, 2024
- 5
Indy Hematology Review
R/R AML: Current, Emerging, and Targeted Therapies
FEATURING
Rami Komrokji
- 356 views
- April 22, 2024
- 3
Indy Hematology Review
Current & Emerging Therapies for AML and MDS
FEATURING
Rami Komrokji
- 166 views
- May 3, 2024
- 1
MyCancerHaven
Experts Discuss How to Approach Frontline Treatment of Unfit Patients With AML
- 105 views
- May 22, 2024
Rush University Medical Center
Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6
FEATURING
Eric Bhaimia
- 343 views
- May 24, 2024
Rush University Medical Center
Selection and Sequencing of Chronic GVHD Therapy
FEATURING
Satyajit Kosuri
- 266 views
- May 24, 2024
- 1
Icahn School of Medicine at Mount Sinai
BPDCN: Current and Future Directions
FEATURING
Naveen Pemmaraju
- 500 views
- May 31, 2024
- 2
Yale Cancer Center
Targeting Apoptosis in Leukemia: Lessons and Challenges
FEATURING
Marina Konopleva
- 110 views
- March 15, 2024
Scripps Health
FLT3-Mutated AML: Advances in Frontline Treatment
FEATURING
Nicholas Short
- 248 views
- March 19, 2024
Insights from 2023 ASH Annual Meeting
FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartinib vs. Standard Chemo
FEATURING
Esther Oliva
- 152 views
- March 22, 2024
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: AML
FEATURING
Farhad Ravandi
- 385 views
- March 25, 2024
- 2
Yale Cancer Center
Splicing Factor Mutations in MDS: Role in Disease Biology and Potential Therapeutic Targeting
FEATURING
Stephanie Halene
- 26 views
- May 15, 2024
Rush University Medical Center
Allo-HSCT Conditioning Regimens: Current Status and Future Directions
FEATURING
Claudio Brunstein
- 266 views
- May 24, 2024
Icahn School of Medicine at Mount Sinai
Boosting MHC:TCR Interactions in AML
FEATURING
Iannis Aifantis
- 28 views
- July 2, 2024
ecancer
Post-Transplant Cyclophosphamide Based GVHD Prophylaxis in Patients Undergoing MMUD HCT
FEATURING
Monzr Al Malki,
Steven Devine
- 42 views
- July 24, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Clinical Study of Oral Azacitidine and Venetoclax in Newly Diagnosed and R/R AML
FEATURING
Maria Amaya
- 2 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independent of Fitness for Intensive Therapy
FEATURING
Justin Watts
- 4 views
- December 16, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ziftomenib + Ven/Aza in R/R NPM1mut or KMT2A-r AML - Interim KOMET-007 Results
FEATURING
Amir Fathi
- 3 views
- December 16, 2024